Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493883 · ClinicalTrials.gov registry record · Phase 1
Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors
A Phase 1 study of Carcinoma, Hepatocellular and Liver Neoplasms, sponsored by Southwestern Regional Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT00493883: Completed Phase 1 study of Carcinoma, Hepatocellular and Liver Neoplasms, sponsored by Southwestern Regional Medical Center.
NCT00493883 is a Phase 1 study of Carcinoma, Hepatocellular and Liver Neoplasms that has completed, run by Southwestern Regional Medical Center. The registered enrollment target is 81 participants, below the 610-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00493883, a Phase 1 study of Carcinoma, Hepatocellular and Liver Neoplasms, has completed, sponsored by Southwestern Regional Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to provide supervised access to treatment with TheraSphere® to eligible patients with primary and metastatic cancer and evaluate response to treatment, survival and toxicity. The study has the following objectives: * Provide supervised access to treatment with TheraSphere to eligible patients with primary and metastatic cancer to the liver. * Evaluate patient experience and toxicities associated with TheraSphere treatment * Evaluate predisposing factors that may influence results and toxicity
Conditions Studied
Interventions
- DEVICE yttrium Y 90 microspheres (TheraSphere®)
Study Locations (1)
Oklahoma
- Cancer Treatment Centers of America at Southwestern Regional Medical Center - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2006-12 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
What the finished NCT00493883 record still lists
NCT00493883 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 610-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Carcinoma, Hepatocellular appearing as the primary indexed condition, and to 1 intervention - of which yttrium Y 90 microspheres (TheraSphere®) is the first listed.
NCT00493883 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT00493883 about?
NCT00493883 is a clinical study titled "Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors". The purpose of this study is to provide supervised access to treatment with TheraSphere® to eligible patients with primary and metastatic cancer and evaluate response to treatment, survival and toxicity. The study has the following objectives: * Provide supervised access to treatment with TheraSph...
What is the current status of trial NCT00493883?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2006-12. Estimated completion is 2011-12.
What conditions does trial NCT00493883 study?
This clinical trial studies the following conditions: Carcinoma, Hepatocellular, Liver Neoplasms.
What interventions are being tested in trial NCT00493883?
The interventions under investigation include: yttrium Y 90 microspheres (TheraSphere®) (DEVICE).
Who is sponsoring clinical trial NCT00493883?
This trial is sponsored by Southwestern Regional Medical Center, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00493883 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Hepatocellular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00493883's enrollment target sits among peer trials
81 16th of 27 higher than 12 of 27 other Carcinoma, Hepatocellular trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Hepatocellular trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
RECRUITING · Phase 1
-
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
COMPLETED · Phase 1
-
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
COMPLETED · Phase 1
-
Sorafenib and TRC105 in Hepatocellular Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia